Open Access Short report

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression

Liv Jonsson1*, Alexander Gaber1, David Ulmert2, Mathias Uhlén34, Anders Bjartell2 and Karin Jirström1

Author Affiliations

1 Department of Clinical Sciences, Pathology, Lund University, Skåne University Hospital, 221 85 Lund, Sweden

2 Department of Clinical Sciences, Division of Urological Cancers, Lund University, Skåne University Hospital, 205 02 Malmö, Sweden

3 Department of Proteomics, AlbaNova University Center, Royal Institute of Technology, 106 91 Stockholm, Sweden

4 Science for Life Laboratory, Royal Institute of Technology, 106 91 Stockholm, Sweden

For all author emails, please log on.

Diagnostic Pathology 2011, 6:91  doi:10.1186/1746-1596-6-91

Published: 28 September 2011

Additional files

Additional file 1:

Patient and tumour characteristics.

Format: DOC Size: 45KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data

Additional file 2:

Association between RBM3 and clinicopathological parameters.

Format: DOC Size: 68KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data